CT-0525
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive
Conditions
HER2-positive
Trial Timeline
Jan 8, 2024 → Mar 31, 2026
NCT ID
NCT06254807About CT-0525
CT-0525 is a phase 1 stage product being developed by Carisma Therapeutics for HER2-positive. The current trial status is active. This product is registered under clinical trial identifier NCT06254807. Target conditions include HER2-positive.
What happened to similar drugs?
0 of 15 similar drugs in HER2-positive were approved
Approved (0) Terminated (0) Active (15)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06254807 | Phase 1 | Active |
Competing Products
20 competing products in HER2-positive